NCT04451408

A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 139 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD, non-Japanese, and Japanese healthy participants who are of first-generation Japanese origin. The study will also investigate how much LY3372993 gets into the bloodstream and will test the effects of LY3372993. The study will be conducted in two parts. The part A includes participants with AD and part B includes healthy participants. Participation could last up to about 61 weeks and may include up to 31 visits to the study center.

Conditions

• Alzheimer Disease
• Healthy

Interventions

Type	Name	Description
DRUG	LY3372993	Administered IV or SC.
DRUG	Placebo	Administered IV or SC.

Timeline

• Start date: 2020-07-07
• Primary completion: 2024-11-18
• Completion: 2024-11-18
• First posted: 2020-06-30
• Last updated: 2025-03-28

Locations

13 sites across 2 countries: United States, Japan

Regulatory

• FDA-regulated drug study